Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma group ...

After leaving consumers hanging for much of the year, the Federal Reserve ultimately lowered rates three times in 2025. On Dec. 10, the central bank instituted a 25-basis-point cut to the federal ...